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Background: Deflazacort is a synthetic corticosteroid characterized by a favourable pharmacokinetic profile,
peculiar pharmacodynamic properties and a good safety profile. However, to the best of our knowledge, no
dose-conversion table based on direct comparison of relative potencies between deflazacort and other main
corticosteroids is currently available in scientific literature.
Main body: This paper, while reporting a brief review of deflazacort pharmacological properties, its efficacy and
tolerability in different clinical areas, has been designed with the specific aim of providing a new dose-conversion table
of corticosteroids, including for the first time also deflazacort.
Short conclusion: We suggest that this new conversion table could be a useful tool for physicians who need to select
the appropriate dose of deflazacort in their clinical practice.
Keywords: Corticosteroids, Deflazacort, Equipotency ratio, Relative potencies, Therapeutic efficacy, Tolerability
Background
Corticosteroids are hormones with 21 carbon atoms;
they are secreted by the adrenal cortex and are tradition-
ally divided into two main groups: glucocorticoids and
mineralocorticoids.
This distinction is based on their preferential biological
activity, i.e. substances that are mainly involved in the
regulation of carbohydrate metabolism (glucocorticoids)
or fluid and electrolyte balance (mineralocorticoids).
The main glucocorticoid produced by the adrenal
cortex is cortisol (also known as hydrocortisone); the main
mineralocorticoid hormone is aldosterone.
Typically, corticosteroids are grouped according to their
relative potency in terms of sodium (Na+) retention, their
effects on carbohydrate metabolism (i.e., gluconeogenesis
and glycogen deposition in the liver) and their anti-
inflammatory activity.
The potency of corticosteroids on carbohydrate metab-
olism is closely related to their anti-inflammatory potency,
as the activation of the same glucocorticoid receptor is
responsible for both metabolic and anti-inflammatory
effects.
On the other hand, the Na+ retaining potency of cortico-
steroids depends on activation of a different mineralocor-
ticoid receptor; therefore, the effects on Na+ retention and
the carbohydrate/antinflammatory actions of corticoste-
roids are not closely related, reflecting selective actions at
distinct receptors (Table 1).
However, classification of corticosteroids into gluco-
corticoids and mineralocorticoids should not be seen as
a strict rule; for example, it has been shown that cortico-
steroids classified in one group can also perform, in
addition to their specific biological activities, certain ac-
tivities that are typical of the other group, although to a
lesser extent. Accordingly, some steroids predominantly
classified as glucocorticoids, such as cortisol and prednis-
one (a synthetic corticosteroid), also have a moderate, but
significant, mineralocorticoid activity; similarly, fludrocorti-
sone, a synthetic corticosteroid with a high mineralocortic-
oid potency, also exhibits a moderate glucocorticoid activity
[1]. Furthermore, activation of glucocorticoid receptor
or mineralocorticoid receptor in the human body does
not rely only on the structure of the drugs, but also onCorrespondence: lparente@unisa.it
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additional factors, including drug metabolism by 11-
beta-hydroxydehydrogenase enzyme, which then can
affect drug concentration both in the bloodstream and
target tissues.
The anti-inflammatory action of corticosteroids is the
main reason for their use as therapeutic agents. In its
early stages, the scientific research on corticosteroids
was oriented towards the synthesis of novel compounds
characterized by a higher anti-inflammatory potency
than cortisone, with a lower incidence of side effects.
This initially led to the development of synthetic
glucocorticoids, such as prednisolone and prednisone,
characterized by a higher anti-inflammatory potency
than natural steroids, with a mineralocorticoid activity
reduced approximately by a half.
Subsequently, other corticosteroids were synthetized,
including fluorinated glucocorticoids such as dexametha-
sone. Even though these drugs are devoid of mineralocor-
ticoid activity, some typical adverse events associated with
their prolonged use have been reported. In fact, cortico-
steroid side effects often adversely affect patients’ quality
of life, and safety issues are especially relevant in some
populations of steroid-treated patients. For example, safety
issues are relevant in children and adolescents, where ster-
oid therapy may result in behavioral disturbances and
growth retardation (due to a not yet fully understood
mechanism, which probably involves abnormalities in GH
release), and in elderly patients, where the risk of steroid
side effects may be enhanced by the frequent presence of
comorbidities requiring pharmacological polytherapy.
More recently, other corticosteroids, including deflaza-
cort, have been synthetized with the main aim of making
available new agents that are better tolerated in each
age group. Deflazacort is a heterocyclic corticosteroid,
oxazoline-derivative of prednisolone [2], characterized
by high efficacy and good tolerability, as demonstrated
by the results of several clinical studies that have evalu-
ated its therapeutic activity and safety in conditions
where corticosteroid treatment is indicated.
In particular, the structural characteristics of deflazacort
can explain some of its peculiar pharmacological activities,
including substantial lack of sodium-retaining activity,
strong anti-inflammatory/immunosuppressive activity, and
lower interference with carbohydrate metabolism and
phosphocalcium metabolism (and, therefore, on growth
and bone turnover) in comparison with older cortico-
steroids [3].
Presently, extensive clinical experience has been gained
on the efficacy of deflazacort in rheumatic diseases in
adults and children, as well as in respiratory, renal, and
hematologic diseases. However, to the best of our know-
ledge, no complete dose-conversion table, based on direct
comparisons of the relative potencies of deflazacort and
other commonly used corticosteroids, is currently avail-
able in scientific literature. In this paper, we briefly review
some of the most relevant clinical trials on deflazacort,
showing its efficacy and tolerability; furthermore, we
propose a new table for the conversion of corticosteroid
doses, elaborated from available literature data, including
both deflazacort and other common steroids used in clin-
ical practice.
Main text
Deflazacort: chemical structure, mechanism of action and
anti-inflammatory potency
Deflazacort is a synthetic corticosteroid, characterized
by the insertion of a methyl-oxazoline ring in the chem-
ical structure of prednisolone 21-acetate [3] (Fig. 1).
After oral administration, deflazacort is rapidly and
completely absorbed in the intestinal tract (peak plasma
concentration is reached within 1–2 hours). Subsequently,
deflazacort is deacetylated at position 21 to form the main
active metabolite, i.e. 21-desacetyl deflazacort [4], which is
characterized by a high binding affinity to tissue gluco-
corticoid receptors [5]. An almost complete elimination of
deflazacort metabolites is reached within 24 hours, mainly
through the kidneys [4].
Glucocorticoids have immunosuppressive and anti-
inflammatory properties, both primarily related to the
antagonism of specific leukocyte functions and to the in-
hibition of the synthesis of pro-inflammatory cytokines.
In vitro, deflazacort significantly inhibits both the prolifer-
ation of mononuclear cells derived from human peripheral
blood, and the release of inflammatory cytokines by these
cells. Deflazacort is also able to inhibit chemotaxis, super-
oxide anion generation and chemiluminescence of human
polymorphonuclear leukocytes in vitro [3].
Studies carried out using different experimental models
indicate that deflazacort is an effective inhibitor of the
early exudative phase of inflammation, as well as of the















The numbers in the Table indicate corticosteroid anti-inflammatory and Na+
retaining potency relative to cortisol (by convention, cortisol = 1), and have
been calculated by the Author on the basis of currently available literature data
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development of chronic granulomatous inflammation.
Furthermore, deflazacort has been shown to inhibit
experimentally-induced chronic inflammatory articular
disease (i.e. adjuvant-induced arthritis).
Studies carried out to evaluate glucocorticoids ability
to induce glycogen deposition in the liver of surrenecto-
mized rats have shown that deflazacort is able to in-
crease gluconeogenesis and hepatic glycogen synthesis,
with a potency of action about 10 times higher than
prednisolone administered at equivalent doses. The anti-
inflammatory potency of deflazacort is about 10–20 times
higher than prednisolone and 40 times higher than cortisol
(hydrocortisone). Furthermore, the duration of action of
deflazacort anti-inflammatory effects is longer than other
glucocorticoids administered at equivalent doses [6].
Deflazacort: therapeutic efficacy
Deflazacort has proven to be effective in the treatment
of various rheumatological disorders including: sarcoid-
osis, a chronic systemic disease of unknown etiology,
characterized by the formation of granulomas in various
organs [7]; juvenile chronic arthritis, a condition character-
ized by alternating periods of remission and exacerbation,
where deflazacort use resulted in clinical improvements in
a group of children with active disease [8]; polymyalgia
rheumatica, which occurs predominantly in elderly patients
with pain and stiffness in the shoulder girdle and pelvis,
where deflazacort was able to induce a significant improve-
ment of clinical outcome parameters (pain intensity and
duration of morning stiffness) and laboratory parameters,
e.g. erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) [9]; rheumatoid arthritis (RA), a disease char-
acterized by progressive, symmetrical, erosive and hyper-
trophic synovitis, often associated with systemic clinical
involvement [10].
A clinical study, which evaluated deflazacort ability to
exert a protective effect on bone erosion and joint dam-
age, typical of RA, has shown that deflazacort is able to
inhibit, in a dose-dependent manner, the invasiveness
and the proliferation of synoviocytes (collected both
from patients with RA and healthy volunteers) through
differential modulation of single components of the fi-
brinolytic system [10].
Deflazacort is indicated in steroid treatment of bronchial
asthma and in the exacerbations of Chronic Obstructive
Pulmonary Disease (COPD), to control inflammation and
increased bronchial reactivity, which are the basis of
bronchospasm. Furthermore, deflazacort is useful in the
treatment of children/adolescents with bronchial asthma.
The efficacy and tolerability of oral deflazacort in acute
moderate asthma in children has been assessed in a pro-
spective, randomized, parallel group trial of children aged
6 to 14 years with a diagnosis of asthma, who presented to
the pediatric emergency department for moderate asthma
exacerbation. Short-acting ß2-adrenergic agonists were ad-
ministered to all patients enrolled in the study; subse-
quently, they received either oral deflazacort (1.5 mg/kg)
or prednisolone (1 mg/kg) for seven days. The primary
outcome measure was Forced Expiratory Volume in one
second (FEV1); secondary outcome measures included
Peak Expiratory Flow Rate (PEFR) and pulmonary symp-
tom score index. Patients were evaluated at the start of
treatment (visit 1), on day 2 (visit 2) and on day 7 (visit 3).
Two children out of the 54 enrolled were hospitalized on
visit 2 (one from each group).
At baseline, clinical data (mean FEV1, PEFR and symp-
tom score) were similar in both groups; on visit 2, all mea-
sures improved: FEV1: +22.2 and +26.5% (p < 0.05); PEFR:
+64 and +49 L/min (p < 0.05); symptom score: −4.4 and
−3.8 (p < 0.05), respectively, without significant differences
between the two groups. Further improvement was ob-
served on visit 3, i.e. FEV1: +33.2 and +32.0% (p < 0.05);
PEFR: +115.7 and +87.6 L/min (p < 0.05); symptom score:
−5.4 and −5.9 (p < 0.05), respectively, without significant
differences between the two groups (Table 2).
Fig. 1 Chemical structures of prednisolone and deflazacort [3]
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In summary, deflazacort and prednisolone demonstrated
similar efficacy in improving pulmonary function and clin-
ical symptoms in the treatment of children with moderate
exacerbations of asthma [11].
Some clinical trials, conducted both in adult and
pediatric populations, have evaluated the use of deflaza-
cort in patients undergoing renal transplantation and in
patients with nephrotic syndrome.
A randomized, double-blind study compared the ef-
fects of treatment with deflazacort versus prednisone on
Bone Mineral Density (BMD), on body composition and
on lipid profile in 24 adult patients with end-stage renal
disease, over a follow-up period of 78 months after kid-
ney transplantation. The analysis of the 17 patients in-
volved in the study (drop-out rates were similar in both
groups) showed that lumbar BMD was significantly re-
duced in prednisone than in deflazacort group (p < 0.05);
furthermore, the whole body BMD decreased from base-
line in prednisone (p < 0.001), but not in deflazacort group.
Lean body mass decreased by approximately 2.5 kg in both
groups after 6–12 weeks (p < 0.001), then remained stable.
Conversely, a significant increase in the fat mass (p < 0.01)
and larger increases in total cholesterol (p < 0.03), in low-
density lipoprotein cholesterol (p < 0.01), and in triglycer-
ides (p < 0.054) were observed in the prednisone group
compared to the deflazacort group. The study concluded
that, in kidney-transplanted patients, the use of deflazacort
is associated with lesser loss of lumbar spine BMD and
whole body BMD compared to prednisone; deflazacort
also helps to prevent fat accumulation and lipid profile
worsening [12].
Another randomized, double-blind study compared
the effects of treatment with deflazacort (0.30 ± 0.03 mg/
kg per day) or methylprednisone (0.20 ± 0.03 mg/kg per
day) on growth, body composition, lipid profile, and
bone mass in pre-puberal patients (n = 27), during a 12-
month follow-up period after kidney transplantation.
The results of this study showed that the maintenance
therapy with deflazacort, in comparison with methyl-
prednisone maintenance therapy, is associated with an
improved linear growth and also prevents excessive
bone loss and fat accumulation in the population of
pre-puberal patients [13].
Nephrotic syndrome, characterized by hypoproteinaemic
edema in association with extensive proteinuria, may occur
as a result of several underlying kidney diseases, the most
common of which are minimal lesion glomerulonephritis
and membranous glomerulonephritis. It is known that
corticosteroid therapy increases the rate of spontaneous
remission in patients with minimal lesion nephrotic
syndrome, and has beneficial effects also in focal and
segmental glomerulosclerosis.
Clinical trials have demonstrated the efficacy of defla-
zacort treatment in both adult and pediatric patients
with nephrotic syndrome. Two clinical trials found that
deflazacort was at least as effective as prednisone in
adult patients with idiopathic nephrotic syndrome (during
a 3-month crossover study) as well as in patients with
minimal change, membranoproliferative, focal segmental
or membranous glomerulonephritis (during a 12-month
double-blind parallel study) [3].
A clinical complication of nephrotic syndrome is
hypogammaglobulinemia (due to increased catabolism
and urinary loss of immunoglobulin) which is associated
with a higher risk of infections, mainly caused by encap-
sulated bacteria. In this respect, some evidence indicate
that IgG2-subclass antibodies are protective against this
type of microorganisms, so that their loss in nephrotic
syndrome is a risk factor for infection.
A study on patients with nephrotic syndrome (n = 11;
mean age 48 months, range 16–52 months) evaluated
the efficacy of deflazacort versus methylprednisolone in
reducing the loss of the different immunoglobulin sub-
classes, during periods of both remission and relapse. In
both treatment groups, a similar return to normal levels of
total IgG and IgG1 was observed, but only those patients
treated with deflazacort showed a significant improvement
in the IgG2 and IgG3 subclasses values [14].
Deflazacort: tolerability
Deflazacort has a smaller impact on calcium metabolism
than any other synthetic corticosteroid, and therefore
shows a lower risk of growth rate retardation in children
[15, 16] and of osteoporosis in adult/elderly patients
[2]. Another distinctive feature of deflazacort is its
smaller influence on carbohydrate metabolism than other
Table 2 Results of pulmonary function tests and symptom scores recorded at baseline (visit 1) and after 2 days (visit 2) and 7 days
(visit 3) of treatment with deflazacort or prednisolone in pediatric patients with moderate asthma exacerbation. Reproduced with
permission from [11]
Visit 1 Visit 2 Visit 3
Deflazacort Prednisolone Deflazacort Prednisolone Deflazacort Prednisolone
FEV1 (%) 53 (13.3) 51 (14.9) 75* (15.8) 78* (20.3) 86*,** (14.3) 84* (18.6)
PEFR (l/min) 169.3 (65.3) 165.4 (79.3) 233* (84.7) 214 (75.5) 285* (113.4) 253* (114.8)
Symptom scores 6.1 (1.4) 6.5 (1.4) 1.7* (1.2) 2.7* (1.2) 0.7*,** (0.8) 0.6*,** (0.8)
*Significantly different (p < 0.05) versus visit 1; **Significantly different (p < 0.05) versus visit 2; FEV1: Forced Expiratory Volume in one second; PEFR: Peak
Expiratory Flow Rate
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glucocorticoids, as demonstrated in both studies con-
ducted on animal models [4] and in clinical trials [17, 18].
Furthermore, the risk of sodium retention and hypokal-
emia, related to the mineralocorticoid activity of the drug,
is greatly reduced with deflazacort in comparison with
older synthetic steroids [3].
Because of its low liposolubility, only a small part of
21-desacetyl-deflazacort, (biologically active metabolite of
deflazacort), crosses the blood–brain barrier [5]. Thus,
when compared with older corticosteroids, deflazacort has
a smaller suppressive effect on hypothalamic-pituitary-
adrenal (HPA) axis, a system that modulate the physiologic
response to stressors and regulate glucose and phosphocal-
cium metabolism and electrolyte balance.
Furthermore, given the minor impact of deflazacort on
the HPA axis, a reduced risk of behavioral disorders com-
pared to other corticosteroids has been hypothesized.
Deflazacort safety in children is a clinically relevant
issue. In fact, when using corticosteroids in pediatric pa-
tients, and especially after long-term treatment, one of
the most alarming adverse event is linear growth retard-
ation; such event could be due to several mechanisms,
the main of which seems to be the inhibition of Growth
Hormone (GH) release from the pituitary gland. In chil-
dren receiving long-term steroid treatment after kidney
transplantation, the substitution of methylprednisolone
(mean dose, 0.2 mg/kg per day) with deflazacort (mean
dose, 0.3 mg/kg per day), over an average period of
15 months, significantly increased GH secretion (p < 0.05)
and mean growth velocity (p < 0.01) [13].
Deflazacort: therapeutic indications and dosage
Deflazacort therapeutic indications include a number
of pathological conditions, i.e.: primary and secondary
adrenocortical failure; rheumatic diseases (including
RA and ankylosing spondylitis); collagen diseases (such
as systemic lupus erythematosus and polymyositis);
dermatological diseases (including pemphigus, severe
psoriasis and mycosis fungoides); allergic states (e.g.,
bronchial asthma and drugs hyper-reactivity); respiratory
diseases (including sarcoidosis and aspiration pneumonia);
ocular diseases (e.g., chorioretinitis and optic neuritis);
hematological diseases (including Hodgkin's disease, non-
Hodgkin's lymphoma, chronic lymphocytic leukemia and
acute childhood leukemia); edematous state (nephrotic
syndrome); gastro-intestinal diseases (ulcerative colitis, re-
gional enteritis).
The initial daily dosage of deflazacort in adults may
range from 6 to 90 mg, depending on the severity and
evolution of the specific disease, and should remain un-
changed, or be modified as appropriate, until a satisfactory
clinical response is observed. It should be emphasized that
corticosteroid requirements vary from patient to patient,
so the dosage should be individualized taking into account
the nature of the disease and the patient's therapeutic
response.The maintenance dose should always be the
minimum dose required to control the symptoms in order
to minimize the risk of side effects; in any case, the dose
should be reduced gradually [6].
Relative potencies and equivalent doses of corticosteroids:
general considerations
Corticosteroids were initially introduced in clinical prac-
tice in the late '40s, when they began to be used for the
treatment of rheumatoid arthritis; since then, cortico-
steroid therapeutic indications have expanded to various
medical areas, including dermatology, rheumatology, im-
munology and oncology. Systemic corticosteroids, which
are used to treat several pathological conditions, are similar
to endogenous steroid hormones produced by the adrenal
cortex, i.e. mineralocorticoid (e.g. aldosterone) and gluco-
corticoids (e.g. cortisol).
Mineralocorticoid are mainly regulated by the renin-
angiotensin system and increase Na+ retention; gluco-
corticoids are mainly regulated by Adrenocorticotropic
Hormone (ACTH) and can exert anti-inflammatory, as
well as metabolic and immunologic effects.
Although all corticosteroids share, to varying degrees,
the properties of both adrenal hormones, some of them
(e.g. fludrocortisone) are essentially used because of their
mineralocorticoid activity, while others (e.g. hydrocortisone,
cortisone, prednisone and prednisolone) are primarily used
for their glucocorticoid effects [19].
The precise knowledge of the characteristics and
physiological effects of corticosteroids is essential to se-
lect the most appropriate drug and to avoid problems
due to its inappropriate use; therefore, the equipotency
ratios between steroids is an important aspect to be con-
sidered in long-term steroid therapy.
The anti-inflammatory potency of cortisol (hydrocorti-
sone) is conventionally equal to 1; hence, based on the
relative potencies of various corticosteroids, it is possible
to identify the equivalent doses of every single steroid.
Table 3 summarizes the relative potencies and the cor-
responding equivalent doses of systemic corticosteroids
according to available literature data [20] (see next
paragraph for deflazacort, as it is not included in this
Table).
Short-acting compounds, such as hydrocortisone (corti-
sol), show lower potencies, while intermediate-acting drugs,
like prednisone and methylprednisolone, are four to five
times more potent than hydrocortisone; dexamethasone, a
long-acting corticosteroid, shows a potency about 25 times
higher than short-acting compounds. Corticosteroids
therapeutic effects may often be associated with side ef-
fects, especially when higher doses and long-term treat-
ment are required. To obtain the maximum benefit from
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therapy, it is important to prevent any potential adverse
event by implementing appropriate preventive measures,
as far as possible [19].
However, it should be emphasized that the risk of side
effects is not only related to corticosteroid dose and dur-
ation of treatment; it also depends on the so-called Drug
Therapeutic Index (DTI), i.e. a ratio that compares the
blood concentration at which a drug becomes toxic to
the concentration at which the drug exerts the desired
therapeutic effect. The drug concentration that produces
a specific effect in a patient is indicated as “individual ef-
fective concentration”; the pharmacological response, in
this case, is defined as "quantal", since the specific effect
may - or may not- occur.
The dose of a drug required to produce a specified
“quantal effect” in 50% of the individuals is the “median
effective dose”, commonly indicated as Effective Dose-50
(ED50). In preclinical studies, the drug “median lethal
dose”, determined on experimental models, is defined as
Lethal Dose-50 (LD50); therefore, in experimental models,
the ratio between LD50 and ED50 indicates DTI.
In clinical studies, the therapeutic index can be deter-
mined by comparing the dose, or the drug concentration
required to cause toxicity, with the concentration re-
quired to produce the therapeutic effects in the studied
population. However, it should be considered that “in vivo”
no drug produces only a single effect, so the therapeutic
index of a drug may be variable depending on the specific
effect that is measured. However, a wider therapeutic index
usually indicates a lower number and severity of side effects
associated with the use of the same drug [1].
Relative potencies and equivalent doses:
deflazacort versus other corticosteroids
Corticosteroid doses used in clinical practice may be
highly variable, depending on the disease to be treated and
its severity. The reference glucocorticoid is prednisone,
usually administered at a dose ranging from 5 to 60 mg/
day. Deflazacort is less potent than prednisone and is usu-
ally administered at proportionately higher doses.
Based on the results of seven clinical trials enrolling a
total of 160 patients, deflazacort is approximately 25%
less potent than prednisone in terms of absolute dosage.
The potency ratio of prednisone to deflazacort is about
1:1.3; e.g., 8 mg of deflazacort elicits a similar biological
response to 6 mg of prednisone.
The dose equivalence of orally administered deflazacort
and prednisone has been evaluated in a large US trial. In
this study, patients with corticosteroid-dependent asthma
or asthmatic bronchitis were treated with prednisone
40 mg/day for a 2 week run-in period, in order to establish
a high baseline corticosteroid dosage level. After this run-
in period, patients were randomised to receive deflazacort
(initial dosage 36 mg/day) or prednisone (initial dosage
30 mg/day); the dose of each drug was progressively re-
duced until the minimum effective dose was reached. The
minimum effective dose was deemed to have been reached
when a minimum of two of the following events was re-
ported: asthma-related awakenings on 2 of 7 consecutive
nights; ≥20% decrease in morning PEFR (versus prior
evening value) on 4 of 7 consecutive mornings; the sum of
patient-assessed symptom scores for 7 consecutive days
was lower than that for the final 7 days of the run-in
Table 3 Relative potencies and equivalent doses of corticosteroids [Modified from 20]
Equivalent glucocorticoid dose (mg) Potency relative to hydrocortisone (cortisol)
(antiiflammatory activity)
Potency relative to hydrocortisone
(cortisol) (mineralcorticoid activity)
Short acting
Hydrocortisone (cortisol) 20 1 1
Cortisone acetate 25 0.8 0.8
Intermediate acting
Prednisone 5 4 0.8
Prednisolone 5 4 0.8
Triamcinolone 4 5 N/A
Methylprednisolone 4 5 0.5
Long acting
Dexamethasone 0.75 30 N/A
Betamethasone 0.6 30 N/A
Mineralcorticoids
Fludrocortisone N/A 15 150
Aldosterone N/A N/A 400
The numbers in the table indicate corticosteroid potency and equivalent doses relative to cortisol (by convention, cortisol = 1), and have been calculated by the
Author on the basis of currently available literature data. N/A, not applicable
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period. On this basis, the minimum effective dose of defla-
zacort was 27.2 mg/day (n = 45) compared with 20.5 mg/
day for prednisone (n = 46), i.e. a ratio of 1.3:1 [3].
The precise determination of the equipotency ratio of
deflazacort versus other glucocorticoids is an important
safety issue with regard to the long-term therapy with these
drugs; for example, glucocorticoid-induced osteoporosis
appears to be dose-dependent and is documented for
prednisolone-equivalent doses ≥5 mg/day.
With regard to the potential of drug-induced osteopor-
osis, an equipotency ratio of deflazacort versus prednisol-
one of 1.2:1 was considered probable in previous studies;
however, more recent data indicate that the correct equi-
potency ratio deflazacort/prednisolone may be at least
1.5:1, and deflazacort/methylprednisolone 1.875:1. Conse-
quently, at standard doses, the osteoporotic potential of
deflazacort appears to be much lower than other steroids.
A clinical study that enrolled 21 male patients with ac-
tive RA or non-axial Psoriatic Arthropathy (PsA), naïve to
steroid treatment, reported useful information to establish
a correct dose-equivalence ratio between low-dose defla-
zacort and methylprednisolone [21]. The patients enrolled
in this study were randomized in two groups: 10 patients
were treated for 6 months with deflazacort 7.5 mg/day
and calcium, cholecalciferol and a Disease-Modifying An-
tirheumatic Drug (DMARD) (Group 1); 11 patients were
treated for 6 months with methylprednisolone 4 mg/day,
calcium, cholecalciferol and a DMARD, and for the fol-
lowing 6 months with deflazacort 7.5 mg/day, calcium,
cholecalciferol and a DMARD (Group 2).
The efficacy of treatment was evaluated in each group
at day 0, 90, 180, 240, and 360. Clinical efficacy parameters
included: number of swollen joints; number of tender
joints; pain measured by means of a Visual Analogue Scale
(VAS); global self-assessment of efficacy expressed separ-
ately by the physician and the patient using a VAS; disabil-
ity index calculated by means of the Health Assessment
Questionnaire (HAQ). Similar trends of efficacy were ob-
served in both groups, with significant improvements of
clinical parameters already evident after 3 months of treat-
ment; these improvements were maintained throughout
the treatment period, regardless of the corticosteroid used.
The study conclusion was that deflazacort is effective in
the treatment of inflammatory arthropathies in male
adults, with a deflazacort/methylprednisolone equivalence
ratio of 1.875:1, and a deflazacort/prednisolone equiva-
lence ratio of 1.5:1 [21].
Other studies, however, suggest that deflazacort/prednis-
olone equivalence ratio may depend on the disease, e.g. ap-
proximately 1.2:1 in rheumatoid arthritis, juvenile chronic
arthritis and nephrotic syndrome, and approximately 1.4:1
in asthma and polymyalgia rheumatica [22]. However, al-
though several studies have determined the equipotency
ratio of deflazacort versus other corticosteroids, to the best
of our knowledge, no dose-conversion table that includes
also deflazacort is so far available in the literature.
Therefore, to facilitate identification of the correct dos-
age of this drug in clinical practice, we propose here a
novel conversion table of corticosteroids doses, elabo-
rated from literature available data (i.e. clinical trials
with sufficiently homogenous study populations) which
also includes deflazacort [1, 3, 19–21] (Table 4).
Conclusion
The anti-inflammatory effect of corticosteroids is one of
the main reasons for the use of these therapeutic agents.
Several studies on adrenal steroids with glucocorticoid
activity have led to the synthesis of new molecules charac-
terized by high anti-inflammatory potency and low inci-
dence of side effects. Safety issues are particularly relevant
in some populations on long-term therapy with corticoste-
roids, such as children and adolescents, in whom steroid
therapy may result in growth retardation and behavioral
disorders, as well as in somewhat "fragile" individuals such
as politreated elderly patients.
Deflazacort is a recent synthetic glucocorticoid character-
ized by high efficacy and good tolerability, as demonstrated
by several clinical studies that have evaluated its therapeutic
efficacy and safety of use. In comparison to older cortico-
steroids, deflazacort shows a high anti-inflammatory and
immunosuppressive activity, and a lower interference
on glucose metabolism, on phosphocalcium metabolism
(hence, on growth and bone turnover), and on HPA axis
functionality, as well as a minimal or absent sodium-
retention effect.
These characteristics are favourable and suggest that
deflazacort can be used safely even in pediatric and eld-
erly populations. Furthermore, deflazacort shows a high
dosage flexibility, due to its wide therapeutic index; in
fact, the initial oral daily dosage of deflazacort in adults
ranges from 6 to 90 mg, depending on the severity and
progression of the specific disease to be treated.
Table 4 Conversion of corticosteroid doses. Elaboration of data
from [1] and [3]
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The precise knowledge of the characteristics and
physiological effects of corticosteroids can assist in the
correct choice of the drug, avoiding potential problems
due to its inappropriate use. Therefore, the exact quanti-
fication of the equipotency ratios between steroids is an
important aspect to consider when using these drugs for
long periods of time.
At present there are few (if any) clinical reasons for
preferentially using any steroid drug and therefore clin-
ical experience, bioavailability and bio-pharmaceutical
factors clearly affect choice of steroid for a given medical
condition; however, knowing the relative potencies and
equivalent doses of corticosteroids in clinical practice is
useful.
We suggest that the new table for the conversion of
corticosteroid doses presented in this paper, which for
the first time includes deflazacort, could provide an aid
to physicians when selecting the appropriate dosage of
corticosteroids to be used in clinical practice.
The evaluation of deflazacort dose range and its thera-
peutic effectiveness in comparison with other corticoste-
roids could be improved by a specific meta-analysis; indeed,
we hope that this paper could stimulate other Authors to
conduct a meta-analysis on these topics.
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